Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that its Turkish distribution partner, ITEM Medical Technologies, has received a significant new order from the National Ministry of Health as it expands usage of the LuViva® Advanced Cervical Scan for screening in 2015. The new order of 100 LuViva devices and 100,000 single-use Cervical Guides supplements previous orders, and is also based in part on the Ministry of Health’s acceptance of LuViva in government training centers and university hospitals. The orders are expected to be filled starting in October.

“This significant purchase order highlights the emerging international recognition of LuViva as a bona fide screening test in developing countries,” said Gene Cartwright, CEO of Guided Therapeutics. “The Turkish Ministry of Health utilized handpicked expert physicians to conduct independent clinical trials to evaluate LuViva for primary screening of cervical cancer, with results released at professional meetings and in letters of support to the Ministry. We expect this current order to be completed over the next 12 months.”

“We believe this is only the beginning of providing expanded cervical cancer screening for Turkish women,” said Zafer Yazici, CEO of ITEM Medical Technologies. “There are approximately 1,000 screening centers in Turkey that would be candidates for LuViva. The test is easy to operate, provides an immediate result and has been well received by both physicians and women in Turkey.”

Cartwright added, “We believe this pattern of independent trials followed by large screening orders will be repeated in other countries where cervical cancer screening is a challenge due to a lack of access to the healthcare infrastructure necessary to administer Pap tests.”

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in our prior financings and our ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent filings.


Contacts

Guided Therapeutics
Bill Wells, 770-242-8723
or
Investors:
Cameron Associates
Alison Ziegler, 212-554-5469